[Updated treatment of achondroplasia]
- PMID: 19252254
[Updated treatment of achondroplasia]
Abstract
In achondroplasia, the mutation is an almost non-variable mutation in the transmembrane part of the receptor, G1138A/C, giving rise to a change in the amino acid sequence at position 380 in the protein (glycine to an arginine residue transition- Gly380Arg [G380R] . In hypochondroplasia, about 30-70% of individuals have been reported to be heterozygous for a mutation in the FGFR3 gene. The most common mutation found is the Asn540Lys (asparagine to lysine transition-N540K) in the intracellular tyrosine-kinase (TK1) region. GH Treatment significantly increased height, growth velocity and z-score of growth velocity GH therapy was more effective in hypochondroprasia than in achondroplasia. Increasing stature in individuals with skeletal dysplasias can also be accomplished by surgical leg lengthening.
Similar articles
-
[Gly380Arg and Asn540Lys mutations of fibroblast growth factor receptor 3 in achondroplasia and hypochndroplasia in the Spanish population].Med Clin (Barc). 1999 Mar 6;112(8):290-3. Med Clin (Barc). 1999. PMID: 10207844 Spanish.
-
[Mutations in the Fibroblast Growth Factor Receptor 3 gene (FGFR3) in Chilean patients with idiopathic short stature, hypochondroplasia and achondroplasia].Rev Med Chil. 2003 Dec;131(12):1405-10. Rev Med Chil. 2003. PMID: 15022403 Spanish.
-
A common FGFR3 gene mutation is present in achondroplasia but not in hypochondroplasia.Am J Med Genet. 1995 Jan 2;55(1):127-33. doi: 10.1002/ajmg.1320550132. Am J Med Genet. 1995. PMID: 7702086
-
[Fibroblast growth factor receptor and achondroplasia].Clin Calcium. 2006 Nov;16(11):1888-93. Clin Calcium. 2006. PMID: 17079857 Review. Japanese.
-
Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia--genetic short limbed dwarfism.Curr Drug Targets. 2003 Jul;4(5):353-65. doi: 10.2174/1389450033490993. Curr Drug Targets. 2003. PMID: 12816345 Review.